AXLRx Book a callCommission

Mid Specialty · Metabolic

Madrigal — Metabolic

Madrigal across Metabolic: the full competitive set, and the 3 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Madrigal report

By therapy area

Therapy area All areas Metabolic

Market All United States

AXLRx reports featuring Madrigal — Metabolic

CI · Metabolic · CI Team · Launch Lead US MASH Competitive Intelligence Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US MASH Disease Landscape The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool. US · In-Market · Read report → P&HTA · Metabolic · Market Access · Medical Affairs US MASH Payer & HTA Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access. US · In-Market · Read report →